Cash Flow Statement

Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Ratios

Silence Therapeutics (SLN) Deferred Taxes (2024 - 2025)

Silence Therapeutics' Deferred Taxes history spans 2 years, with the latest figure at $1000.0 for Q3 2025.

On a quarterly basis, Deferred Taxes fell 97.96% to $1000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $11000.0, a 98.7% decrease, with the full-year FY2025 number at $11000.0, down 98.7% from a year prior.
Deferred Taxes hit $1000.0 in Q3 2025 for Silence Therapeutics, down from $10000.0 in the prior quarter.
Over the last five years, Deferred Taxes for SLN hit a ceiling of $324000.0 in Q4 2024 and a floor of $1000.0 in Q3 2025.